Individualized prediction of lung-function decline in chronic obstructive pulmonary disease
暂无分享,去创建一个
D. Postma | B. McManus | S. Lam | R. Ng | J. Vonk | J. Connett | D. Sin | S. Bryan | R. Wise | M. Sadatsafavi | D. Tashkin | S. Man | C. M. Tammemagi | C. Löfdahl | Z. Zafari | R. Khakban | Z. Hollander | D. D. Sin | C. M. Tammemagi
[1] Shinu Abraham,et al. Lung-function trajectories leading to chronic obstructive pulmonary disease , 2015 .
[2] E. Ford. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. , 2015, Chest.
[3] S. Lam,et al. Plasma pro-surfactant protein B and lung function decline in smokers , 2015, European Respiratory Journal.
[4] Mark A. Pitt,et al. Model Evaluation and Selection , 2014 .
[5] T. Prentice. World Health Report , 2013 .
[6] S. Lam,et al. Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.
[7] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[8] L. Edwards,et al. Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.
[9] D. Mannino,et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.
[10] MPH Dr. Stacey Sheridan MD,et al. Framingham-based tools to calculate the global risk of coronary heart disease , 2007, Journal of General Internal Medicine.
[11] N. Anthonisen,et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.
[12] D. Postma,et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .
[13] D. Postma,et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.
[14] J L Hankinson,et al. Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.
[15] G. Owens. The Lung Health Study. , 1996, Current opinion in pulmonary medicine.
[16] W. Bailey,et al. Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .
[17] W. Bailey,et al. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. , 1993, Controlled clinical trials.
[18] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[19] M. Segal,et al. Analysis of dose-response curves to methacholine. An approach suitable for population studies. , 1987, The American review of respiratory disease.
[20] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.